LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) is investigating claims on behalf of investors of Rockwell Medical, Inc. (“Rockwell Medical” or the “Company”) (NASDAQ: RMTI) concerning the Company and its officers’ possible violations of federal securities laws.
On September 9, 2015, Rockwell Medical disclosed the U.S. commercial launch of Triferic, a FDA approved iron product designed to replace iron and preserve hemoglobin in hemodialysis patients in the United States. On February 29, 2016, Rockwell Medical’s CFO Tom Klema revealed to investors on a conference call that sales of Triferic were “immaterial” for 2015; and in response analysts questioned the Company’s commercial viability in the dialysis arena.
On this news, shares of Rockwell Medical fell $3.29 per share, or over 34%, to close on March 1, 2016 at $6.31 per share.
If you purchased Rockwell Medical securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.